Zentalis Pharmaceuticals (NASDAQ:ZNTL) Lowered to “Neutral” at UBS Group

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Free Report) was downgraded by UBS Group from a “buy” rating to a “neutral” rating in a report issued on Thursday, Marketbeat.com reports. They currently have a $5.00 target price on the stock, down from their prior target price of $28.00. UBS Group’s price target indicates a potential upside of 5.26% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Oppenheimer decreased their target price on Zentalis Pharmaceuticals from $50.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday. Morgan Stanley reaffirmed an “equal weight” rating and issued a $8.00 price objective (down from $38.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday. Jefferies Financial Group reissued a “hold” rating and set a $6.00 target price (down previously from $42.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday. Stifel Nicolaus lowered their price target on shares of Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, HC Wainwright reduced their price objective on Zentalis Pharmaceuticals from $40.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $11.33.

View Our Latest Report on Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL opened at $4.75 on Thursday. The business’s 50-day moving average is $11.16 and its 200 day moving average is $12.97. Zentalis Pharmaceuticals has a 1 year low of $3.93 and a 1 year high of $29.63. The firm has a market capitalization of $337.39 million, a P/E ratio of -1.42 and a beta of 1.83.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.77) by $0.91. The company had revenue of $40.56 million during the quarter, compared to analysts’ expectations of $35.00 million. During the same period in the previous year, the business earned ($1.07) earnings per share. On average, analysts expect that Zentalis Pharmaceuticals will post -2.72 EPS for the current year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, insider Diana Hausman sold 3,356 shares of the business’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $12.62, for a total transaction of $42,352.72. Following the completion of the sale, the insider now directly owns 373,876 shares in the company, valued at approximately $4,718,315.12. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Zentalis Pharmaceuticals news, CFO Cam Gallagher sold 9,597 shares of the company’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $11.98, for a total value of $114,972.06. Following the completion of the sale, the chief financial officer now directly owns 633,680 shares in the company, valued at approximately $7,591,486.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Diana Hausman sold 3,356 shares of Zentalis Pharmaceuticals stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $12.62, for a total transaction of $42,352.72. Following the transaction, the insider now directly owns 373,876 shares in the company, valued at $4,718,315.12. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Eventide Asset Management LLC boosted its stake in Zentalis Pharmaceuticals by 47.9% during the fourth quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock worth $175,134,000 after buying an additional 3,745,936 shares during the period. Decheng Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $31,809,000. Price T Rowe Associates Inc. MD increased its stake in Zentalis Pharmaceuticals by 20.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after buying an additional 585,644 shares during the period. Vanguard Group Inc. increased its position in shares of Zentalis Pharmaceuticals by 6.2% during the third quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock worth $105,047,000 after acquiring an additional 307,490 shares during the period. Finally, Federated Hermes Inc. increased its holdings in Zentalis Pharmaceuticals by 10.9% during the 4th quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock worth $32,733,000 after purchasing an additional 212,872 shares during the period.

Zentalis Pharmaceuticals Company Profile

(Get Free Report)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Featured Stories

Analyst Recommendations for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.